Compare Petróleo Brasileiro SA (PBR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Regeneron Pharmaceuticals Inc — how do they compare? Petróleo Brasileiro SA trades at $20.94 (market cap $128.30B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Petróleo Brasileiro SA is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (8.07%). Which is the better fit depends on your goals.
| PBR | REGN | |
|---|---|---|
Market Cap | $128.30B | $83.43B |
Sector | Technology | Health |
52-Week High | $22.03 | $852.03 |
52-Week Low | $11.54 | $555.51 |
Enterprise Value | $188.72B | $78.14B |
Dividend Yield | 8.07% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $20.83, up 3.53% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a low P/E of 5.26, robust net income margin of 24.52%, and record Q2 2026 earnings beating estimates. Recent news highlights regulatory approvals for new drilling in Brazil and exploration in Ghana, signaling growth potential.
Outlook is positive given low valuation, high profitability, and expansion efforts, but risks include geopolitical factors and oil price volatility. Analyst consensus leans bullish with 50% buy ratings, though the stock faces headwinds from softer crude prices and execution risks in new projects.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
